secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001213900-24-096804
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD narrows Q3 net loss to $567K; license revenue rises to $547K
---------------------------------------------------------------------------

- Net loss from continuing operations of $567K ($0.05 per share) vs. $1.4M loss ($0.13) in Q3 2023.
- License revenue from Mayne agreement totaled $547K, up from negative $53K in Q3 2023.
- Total operating expenses fell 18.3% YoY to $1.4M on cost reductions after royalty transition.
- Cash and equivalents stood at $5.0M as of Sept 30, 2024.
- Company continues to evaluate strategic alternatives including M&A or asset sale; no timeline set.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/0001213900-24-096804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000121390024096804/ea0220593-8k_therap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-096804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer